(AGENPARL) - Roma, 6 Febbraio 2025 - (AGENPARL) – gio 06 febbraio 2025 7.00 AM CET / 6-Feb-2025 / Hansa Biopharma AB (STO:HNSA)
IDEFIRIX Product Sales Increased 83% Compared to the Prior Year
Lund, Sweden, February 6, 2025, Hansa Biopharma AB, Hansa or the Company (Nasdaq
Stockholm: HNSA) today announced its full year and Q4 2024 financial results.
Søren Tulstrup, President and CEO, Hansa Biopharma said, “2024 proved to be a
transformative year for Hansa, marked by ongoing commercial success of
IDEFIRIX[®] across Europe and the achievement of key pipeline milestones in our
priority therapy areas – Autoimmune, Gene Therapy, and Transplantation.
Importantly, 2024 IDEFIRIX product sales, excluding the impact of a 49.6 MSEK
provision to account for retroactive price adjustments linked to successful
special early access programs following IDEFIRIX’s launch in 2020, totaled 189.7
MSEK which represents an 83% increase over the prior year (103.7 MSEK).
Including the impact of the provision, 2024 IDEFIRIX product sales totaled 140.1
MSEK which represents a 35% increase over prior year (103.7 MSEK) while total
2024 sales (171.3 MSEK) increased by 28% compared to the prior year (134.1
MSEK). The year-on-year IDEFIRIX growth reflects the continued successful launch
execution in Europe and the ongoing momentum we are creating in the clinical
community to help drive greater utilization of IDEFIRIX. Q4 2024 IDEFIRIX
product sales were 25.6 MSEK and despite strong full year sales, quarterly
product sales continue to fluctuate given the unpredictable nature of the
European kidney allocation systems and availability of organs.”
Tulstrup continued, “Our efforts to advance our exciting pipeline of drug
candidates resulted in the achievement of several key milestones, including
positive results from a Phase 2 study and indirect treatment comparison of
imlifidase in Guillain-Barré Syndrome (GBS), a favorable 12-month analysis from
the NICE-01 study of HNSA-5487, completion of enrolment in our GOOD-IDES-02
Phase 3 study of imlifidase in anti-GBM, and the initiation of a Phase 2 trial
of imlifidase in Crigler-Najjar for patients with anti-AAV antibodies in
collaboration with our gene therapy partner, Genethon.”
Financial Performance
Revenue for the full year 2024 totaled 220.9 MSEK excluding the impact of a 49.6
MSEK provision. The provision reflects price adjustments linked to successful
early access programs following IDEFIRIX’s launch in 2020. Excluding the
provision, full year 2024 revenue totaled 171.3 MSEK representing a 28% increase
over the prior year (134.1 MSEK). In 2024 IDEFIRIX product sales, excluding the
provision, totaled 189.7 MSEK which represents an 83% increase over the prior
year (103.7 MSEK). Including the provision, 2024 IDEFIRIX product sales totaled
140.1 MSEK which represents a 35% increase over prior year (103.7 MSEK).
In Q4 2024, Hansa reported total revenue of 32.3 MSEK and IDEFIRIX product sales
of 25.6 MSEK. Despite the strong performance of IDEFIRIX in 2024, Hansa product
sales continue to fluctuate due to variations in European kidney allocation
systems impacting availability of organs to specific patients.
Pipeline Progress
Progress across the company’s pipeline continues with a positive read out from
the Phase 2 15-HMedIdeS study in Guillain-Barré Syndrome (GBS) and an indirect
treatment comparison of imlifidase to the International Guillain-Barré Syndrome
Outcome Study (IGOS). In the Phase 2 study, patients treated with imlifidase
plus IVIg had rapid overall improvement in functional status – specifically 37%
of patients in the study returned to walking independently at one week. In the
indirect treatment comparison to the IGOS-IVIg group, patients experienced
significantly faster improvement across clinically relevant measures including
median time to return to walking independently six weeks sooner than the IVIg
-comparator group.
The Company also shared positive results from a 12-month follow-up analysis from
the NICE-01 trial of HNSA-5487, assessing IgG recovery, immunogenicity and
redosing potential. In the analysis, HNSA-5487 reduced IgG levels by more than
95% in a few hours and achieved lower peak anti-drug antibody (ADA) responses
confirming its redosing potential. In the first half of 2025, the Company plans
to meet with regulatory agencies to establish a clinical pathway focused on
neuro-autoimmune disease.
The Company’s Phase 3 GOOD-IDES-02 study in anti-GBM completed enrolment and
data read out is expected in the second half of 2025. The Post Authorization
Efficacy and Safety (PAES) study in kidney transplantation continued to enroll
patients (96%) and is expected to be completed in mid-2025. A Phase 2 trial, GNT
-018-IDES, in patients with Crigler Najjar syndrome with pre-existing antibodies
against adeno-associated (AAV) vectors was initiated in collaboration with
Genethon. Finally, the ConfideS Phase 3 US pivotal trial in kidney
transplantation completed enrolment in 2024 and a data read out is expected in
the second half of 2025. This will provide the basis for the Company’s Biologics
License Application (BLA) with the U.S. Food and Drug Administration (FDA) in
the second half of 2025.
Financial Summary
[][]
2023
– unaudited
134.1
Provision[1] – – (49.6)
134.1
revenue
after
provision
SG&A expenses (88.5) (106.0) (343.8)
(450.5)
R&D expenses (101.4) (108.3) (375.7)
(411.3)
Loss from operations (173.7) (175.5) (637.4)
(788.5)
Loss for the period (276.4) (124.5) (806.7)
(831.7)
Net cash used in operations (206.8) (172.9) (733.9)
(755.7)
Cash and short-term 405.3 732.1 405.3
732.1
investments
EPS before and after dilution (4.08) (2.36) (12.84)
(15.83)
(SEK)
Number of outstanding shares 67,814,241 52,671,796 67,814,241
52,671,796
52,540.089
shares before and after
dilution
the period
[1] Actual product sales for the full year 2024 totaled 189.7 MSEK. Sales were
offset by a provision totaling 49.6 MSEK associated with volume discounts and
rebates. Including the provision, year to date product sales totaled 140.1
MSEK.
Conference Call Details
Hansa Biopharma will host a telephone conference today Thursday, February 6,
2025, at 14:00 CET / 8:00 am ET.
The event will be hosted by Søren Tulstrup, President and CEO, Evan Ballantyne,
CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim
results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be live on the company website during the
call under Events &
Presentations (https://www.hansabiopharma.com/investors/presentations-events/)
and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details
provided below:
Participant Dial In (Toll Free): 1-833-821-3542
Participant International Dial In: 1-412-652-1248
*Please ask to be joined into the Hansa Biopharma call
Join the webcast here:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=8Ylnk0T5
For the full financial calendar and list of events in 2025 please visit
https://www.hansabiopharma.com/investors/calendar/
This is information that Hansa Biopharma AB is obliged to make public pursuant
to the Securities Markets Act. The information was submitted for publication at
7:00 CET on 2025-02-06.
— ENDS —
For more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a second-generation IgG cleaving molecule
with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has
operations in Europe and the U.S. The company is listed on Nasdaq Stockholm
under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2Lk45GKmbM27Qh8EoCvDduQqWr9uZ5n3zJkmRCWQs4qJc3g3aUfyMjrHPjQ9BCyNVQRaojFbvGtKeVAk3yL2DyFSGmxBHNELRg1QwQ5SJqXP4L.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2Lk45GKmbM27Qh8EoCvDduQqWr9uZ5n3zJkmRCWQs4qJc3g3aUfyMjrHPjQ9BCyNVQRaojFbvGtKeVAk3yL2DyFSGmxBHNELRg1QwQ5SJqXP4L.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Condono, Bonelli (AVS): «Meloni come Berlusconi. Legalizza le illegalità e punisce i cittadini onesti»
- Agenzia nr. 2157 – Sanità, Mazzotta (FI): “Depositata la proposta di legge per l’Osservatorio regionale sul diritto alla cura
- ASL Lecce: Screening oncologici nelle persone trans e gender diverse, esperti a confronto per una prevenzione più inclusiva
- Il Vescovo Augusto ‘paroliere’ in “Come una cerva anela” oratorio musicale con oltre 100 elementi sabato 21 e domenica 22 nelle cattedrali di Pescia e Pistoia con le musiche del Maestro Giovanni Proietti Modi
- Saldo IMU, arrivano gli assistenti digitali: risposte chiare e personalizzate 24 ore su 24
- Cs. n.457 Il 20 novembre un convegno per l’infanzia e l’adolescenza il Comune, di Ragusa presenta i risultati dei progetti educativi + locandina
- La musica delle parole: a Monopoli arriva Play Your Voice
- Screening nella Casa di Comunità di Senise
- Antisemitismo, Giglio Vigna (Lega): Legge di civiltà, la sinistra attacchi Hamas con lo stesso vigore
- UGEI: “DDL ANTISEMITISMO APPROVATO, L’ITALIA SCEGLIE DI NON VOLTARSI DALL’ALTRA PARTE”